Results 351 to 360 of about 326,995 (379)
Some of the next articles are maybe not open access.
Adoptive Immunotherapy of Melanoma
2011Adoptive immunotherapy involves the ex vivo manipulation and expansion of lymphocytes to treat cancer. These lymphocytes, or effector cells, are “adoptively” transferred into the recipient and may be infused alone or as part of a regimen that includes chemotherapy, radiation therapy, exogenous cytokines and/or other biologic agents (e.g., antibodies ...
Seth M. Pollack, Cassian Yee
openaire +2 more sources
2004
Adoptive transfer originally referred to the ability to confer protective immunity on a naive host via infusion of T lymphocytes from an immune donor. This term now also encompasses a strategy of cancer therapy in which autologous T cells are acquired from a tumor-bearing host then activated and numerically expanded ex vivo prior to reinfusion.
Gregory E. Plautz +3 more
openaire +2 more sources
Adoptive transfer originally referred to the ability to confer protective immunity on a naive host via infusion of T lymphocytes from an immune donor. This term now also encompasses a strategy of cancer therapy in which autologous T cells are acquired from a tumor-bearing host then activated and numerically expanded ex vivo prior to reinfusion.
Gregory E. Plautz +3 more
openaire +2 more sources
Mononuclear Cell Adoptive Immunotherapy
Hematology/Oncology Clinics of North America, 1994In contrast with red cells, platelets, and granulocytes, hemotherapy using lymphocytes and monocytes is only beginning to be explored. Blood banks and transfusion services, the traditional sources of expertise in sterile cell processing, storage, and transfusion, have played an integral role in the early technical development of mononuclear cell ...
Harvey G. Klein, Jong-Hoon Lee
openaire +3 more sources
Adoptive immunotherapy for herpesviruses
2007Herpesvirus infections rarely cause significant problems in the immunocompetent human host. However, in the immunosuppressed, for example, recipients of hematopoietic stem cell transplants (HSCT) (Rooney et al., 1998), solid organ transplants (SOT), or human immunodeficiency virus (HIV)-infected individuals, viral infections/reactivations are common ...
Catherine M. Bollard +3 more
openaire +2 more sources
Review: Cardiopulmonary Toxicity of Adoptive Immunotherapy
The American Journal of the Medical Sciences, 1988Adoptive immunotherapy, the administration of interleukin-2 (IL-2) and interleukin-2 activated cells, leads to tumor regression in some patients with advanced cancer. Although this new therapeutic modality offers hope for the future, at present, a multitude of toxicities limit the total dose and duration of therapy.
Alpha A. Fowler +5 more
openaire +2 more sources
Adoptive Immunotherapy of Ovarian Carcinoma
Gynecologic Oncology, 2002SCOPUS: le.j ; info:eu-repo/semantics ...
de Gramont, Aimery +5 more
openaire +2 more sources
NK cell adoptive immunotherapy
Blood, 2005Comment on Miller et al, page [3051][1] In this issue of Blood, Miller and colleagues present data on the administration of haploidentical NK cells to cancer patients. They identify a feasible and safe method for in vivo NK cell expansion and clinical efficacy.
openaire +4 more sources
An artificial solution for adoptive immunotherapy
Trends in Biotechnology, 2003Abstract Adoptive immunotherapy is a promising strategy in the battle against cancer and infectious diseases and the recently developed artificial antigen-presenting cell (aAPC) overcomes several obstacles for this therapy. The aAPC recapitulates the natural in vivo antigen-presenting cell (APC)–T cell interactions by coupling human leukocyte ...
openaire +3 more sources
Adoptive T‐cell transfer in cancer immunotherapy
Immunology & Cell Biology, 2006Adoptive T‐cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self‐antigens and success has been limited in part by inadequate persistence and expansion of transferred
Tey, Siok-Keen +2 more
openaire +4 more sources
Lab on a Chip, 2015
Current transfection technologies lead to significant inter-clonal variations. Previously we introduced a unique electrotransfection technology, Nanochannel-Electroporation (NEP), which can precisely and benignly transfect small cell populations (~100 ...
Lingqian Chang +12 more
semanticscholar +1 more source
Current transfection technologies lead to significant inter-clonal variations. Previously we introduced a unique electrotransfection technology, Nanochannel-Electroporation (NEP), which can precisely and benignly transfect small cell populations (~100 ...
Lingqian Chang +12 more
semanticscholar +1 more source